This is correct. Covid was just a bonus. But Covid indication is what got us here, and to $10 previously. So always having the HIV indication in mind, that’s what the drug was made for, but I sure hope they’ve got this one under control. The near term fate of the stock rests in their handling of, and the actual results of these few trials.
News 
Market Data 
Discover 
